Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) shot up 0.9% on Friday. The stock traded as high as $1.1899 and last traded at $1.13. 29,088 shares were traded during mid-day trading, a decline of 27% from the average daily volume of 39,728 shares. The stock had previously closed at $1.12.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 31st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.00.
View Our Latest Stock Analysis on Alzamend Neuro
Alzamend Neuro Trading Up 0.9%
The company has a market capitalization of $5.46 million, a price-to-earnings ratio of -0.49 and a beta of 0.27. The stock’s fifty day simple moving average is $1.58 and its 200-day simple moving average is $1.32.
Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last posted its quarterly earnings results on Thursday, September 10th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.12). On average, analysts anticipate that Alzamend Neuro, Inc. will post -1.05 EPS for the current fiscal year.
Hedge Funds Weigh In On Alzamend Neuro
A hedge fund recently raised its position in Alzamend Neuro stock. Kingsbury Capital Investment Advisors LLC increased its position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 134.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,329,100 shares of the company’s stock after buying an additional 762,367 shares during the period. Alzamend Neuro comprises about 1.3% of Kingsbury Capital Investment Advisors LLC’s portfolio, making the stock its 18th biggest position. Kingsbury Capital Investment Advisors LLC owned 27.75% of Alzamend Neuro worth $1,595,000 at the end of the most recent reporting period. Institutional investors own 49.61% of the company’s stock.
Alzamend Neuro Company Profile
Alzamend Neuro, Inc (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders. Its primary research efforts have centered on Alzheimer’s disease and related conditions, with additional potential applications in disorders such as bipolar disorder, post-traumatic stress disorder and major depressive disorder.
The company’s lead product candidate, AL001, is based on a proprietary ionic cocrystal technology intended to deliver lithium in a formulation designed for the treatment of Alzheimer’s disease and other neurological conditions.
Featured Articles
- Five stocks we like better than Alzamend Neuro
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
